Along this line, talniflumate, the anti-inflammatory pro-drug of the common TMEM16A-inhibitor NFA that was originally developed by Argentinian Laboratorios Bago, increased survival of CF mice remarkably (Walker et al., 2006). Here, ANO1 is linked to cystic fibrosis.